References
- Evaluate pharma, world preview 2016, outlook to 2022. 9th ed. 2016 Sep. Available from: http://info.evaluategroup.com/rs/607-YGS-364/images/WP2017-SUM.pdf
- Available from: http://www.nasdaq.com/article/generic-drugs-revolutionary-change-in-the-global-pharmaceutical-industry-cm576603
- U.S. Department of Commerce . International Trade Administration, Industry & Analysis. Available from: www.trade.gov/topmarkets
- Yu Y , Gupta S. Pioneering advantage in generic drug competition. Int J Pharm Healthc Marketing. 2014;8(2):126–150.
- Burdon M , Sloper K. The art of using secondary patents to improve protection. Int J Med Market. 2003;3(3):226–238.
- Darrow JJ. Debunking evergreening patents myth. Harvard Law Record. 2010;131(3):1–3.
- Engelberg AB . Special patent provisions for pharmaceuticals: have they outlived their usefulness? A political, legislative and legal history of U.S law and observations for the future, IDEA. J Law Technol. 1999;39(3):389–432.
- Fleming E , Ma P . Drug life cycle technologies. Nat Rev Drug Discov. 2002;1:751–752.
- Hutchins M . Extending the monopoly – how Secondary patents can be used to delay or prevent generic competition upon expiry of the basic product patent. J Gene Med. 2003;1(1):57–71.
- Lloyd M . Evergreening by whom? A review of secondary patents for omeprazole. Pharmaceut Patent Analyst. 2013;2(6):737–743.
- Ohly CD Omeprazole is Over - Or Nearly So; 2008 [cited 2015 Dec 20] . Originally published on Spicy IP. Available from: www.genericsweb.com
- Paine CS . Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering. Setan Hall Law Rev. 2003;33(2):479–510.
- Rathod SK . Ever-greening, a status check in selected countries. J Gene Med. 2010;7(3):227–242.
- Yoshitani RS , Cooper ES . Pharmaceutical reformulation: the growth of life cycle management. Houstan J Health Law Policy. 2007;7(1):379–410.
- Granstrand O , Tietze F . IP strategies and policies for and against evergreening. European Policy for Intellectual Property, 2014. In: Brussels paper presented at the conference, CIM working paper. 2014.
- Pereira da Viega CR , Periera da Veiga C , Corso JMD , et al. Strategy of innovation’s management in the pharmaceutical industry holds intellectual property. Am J Indust Business Manage. 2013;3:565–572.
- Kiran S , Kulkarni M . Secondary patents in pharmaceutical industry, Omeprazole: a case study. 2016 Dec. Available from: http://www.inderscience.com/jhome.php?jcode=ijipm#issue
- Manuscript under preparation .
- Germeraad P . Integration of intellectual property strategy with innovation strategy. Res Technol Manag. 2010;53(3):10–18.
- Terstappen CG , Reggiani A . In silico research in drug discovery. TRENDS Pharm Sci. 2001;22(1):23–26.
- The Drug Development Process . Available from: https://www.fda.gov/forpatients/approvals/drugs/default.htm
- Sternitzke C . An exploratory analysis of patent fencing in pharmaceuticals: the case of PDE5 inhibitors. Res Policy. 2013;42(2):542–551.